COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]

Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and C...

Full description

Bibliographic Details
Main Authors: Rodrigo M. Carrillo-Larco, Carlos Altez-Fernandez, Sabrina Ravaglia, Joaquín A. Vizcarra
Format: Article
Language:English
Published: Wellcome 2020-09-01
Series:Wellcome Open Research
Online Access:https://wellcomeopenresearch.org/articles/5-107/v2
id doaj-f1a57f544ba545a895498b9e39abc70d
record_format Article
spelling doaj-f1a57f544ba545a895498b9e39abc70d2020-11-25T03:18:54ZengWellcomeWellcome Open Research2398-502X2020-09-01510.12688/wellcomeopenres.15987.217955COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]Rodrigo M. Carrillo-Larco0Carlos Altez-Fernandez1Sabrina Ravaglia2Joaquín A. Vizcarra3CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, PeruFacultad de Medicina Alberto Hurtado, Universidad Peruana Cayetano Heredia, Lima, PeruIRCCS C., Mondino Foundation, Pavia, ItalyDepartment of Neurology, Emory University, Atlanta, USABackground: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23 rd, 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. The age ranged between 23 and 77 years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The protein levels in cerebrospinal fluid samples ranged between 40 and 193 mg/dl. None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.https://wellcomeopenresearch.org/articles/5-107/v2
collection DOAJ
language English
format Article
sources DOAJ
author Rodrigo M. Carrillo-Larco
Carlos Altez-Fernandez
Sabrina Ravaglia
Joaquín A. Vizcarra
spellingShingle Rodrigo M. Carrillo-Larco
Carlos Altez-Fernandez
Sabrina Ravaglia
Joaquín A. Vizcarra
COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
Wellcome Open Research
author_facet Rodrigo M. Carrillo-Larco
Carlos Altez-Fernandez
Sabrina Ravaglia
Joaquín A. Vizcarra
author_sort Rodrigo M. Carrillo-Larco
title COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
title_short COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
title_full COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
title_fullStr COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
title_full_unstemmed COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
title_sort covid-19 and guillain-barre syndrome: a systematic review of case reports [version 2; peer review: 2 approved]
publisher Wellcome
series Wellcome Open Research
issn 2398-502X
publishDate 2020-09-01
description Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23 rd, 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. The age ranged between 23 and 77 years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The protein levels in cerebrospinal fluid samples ranged between 40 and 193 mg/dl. None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.
url https://wellcomeopenresearch.org/articles/5-107/v2
work_keys_str_mv AT rodrigomcarrillolarco covid19andguillainbarresyndromeasystematicreviewofcasereportsversion2peerreview2approved
AT carlosaltezfernandez covid19andguillainbarresyndromeasystematicreviewofcasereportsversion2peerreview2approved
AT sabrinaravaglia covid19andguillainbarresyndromeasystematicreviewofcasereportsversion2peerreview2approved
AT joaquinavizcarra covid19andguillainbarresyndromeasystematicreviewofcasereportsversion2peerreview2approved
_version_ 1724625087629361152